DHE is a migraine-specific acute medication first approved in 1946. The FDA's approval of the nasal powder formulation, ...

"DHE plays a unique clinical role in the acute treatment of migraine, providing patients long-lasting effects and the unique ...

Montgomery County is attributing a dramatic decline in drug deaths to efforts to prevent them, including availability of a ...

The FDA has approved Atzumi (dihydroergotamine) nasal powder for the acute treatment of migraine with or without aura in adults.

The US Food and Drug Administration (FDA) has approved Atzumi, a 5.2 mg dihydroergotamine (DHE) nasal powder, for the acute ...

An antidepressant containing a form of the drug ketamine has been added to the Pharmaceutical Benefits Scheme (PBS), making ...

Kindeva manufactures nasal-based drugs. It celebrated the opening of its new building and recent expansion Thursday.

Can’t breathe without your nasal spray? You’re not alone. But here’s why that quick fix can cause long-term harm.

The recommended dose of Atzumi is 5.2mg, the contents of 1 nasal device, administered into 1 nostril. The Food and Drug Administration (FDA) has approved Atzumi ™ (dihydroergotamine) nasal ...

Approval is based on results from the Phase III ASCEND trial, in which patients using the powder achieved freedom from pain ...

Kindeva Drug Delivery, located off of Newtown Pike and Citation Boulevard, specializes in manufacturing life-saving ...